# US 2003/0073094 A1 · Stress proteins and uses therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0073094 A1
- Document ID: US20030073094A1
- Status: Published application
- Kind: A1
- Application number: 10/046,649
- Filed: 2002-01-14
- Published: 2003-04-17
- Earliest claimed: 1988-06-15
- Assignees: Whitehead Institute for Biomedical Research
- Inventors: Richard A. Young; Douglas Young
- Web page: https://patentgrep.com/patent/US20030073094A1

## CPC

- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 39/04: Mycobacterium, e.g. Mycobacterium tuberculosis
- A61K 39/12: Viral antigens
- A61K 39/385: Haptens or antigens, bound to carriers
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 14/005: from viruses
- C07K 14/35: from Mycobacteriaceae (F)
- C12N 15/62: DNA sequences coding for fusion proteins
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/6043: {Heat shock proteins}
- A61K 2039/70: {Multivalent vaccine}
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/20: containing a tag with affinity for a non-protein ligand
- C07K 2319/21: containing a His-tag
- C07K 2319/35: containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C07K 2319/50: containing protease site
- C07K 2319/735: containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
- C07K 2319/75: containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
- C12N 2740/16222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to stress proteins and methods of modulating an individual's immune response. In particular, it relates to the use of such stress proteins in immune therapy and prophylaxis, which results in an induction or enhancement of an individual's immune response and as an immunotherapeutic agent which results in a decrease of an individual's immune response to his or her own cells. The present invention also relates to compositions comprising a stress protein joined to another component, such as a fusion protein in which a stress protein is fused to an antigen. Further, the present invention relates to a method of generating antibodies to a substance using a conjugate comprised of a stress protein joined to the substance.

## Claims

### Claim 1

A vaccine comprising all or a portion of a stress protein which induces an immune response in an individual to whom it is administered or all or a portion of a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of the stress protein to be capable of inducing an immune response in an individual to whom it is administered.

### Claim 2 (depends on 1)

A vaccine of claim 1 in which the stress protein is a mycobacterial stress protein or a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of the mycobacterial stress protein to induce an immune response in the individual to whom it is administered.

### Claim 3

A vaccine for use in enhancing in an individual the immune response to a pathogen, comprising all or a portion of a stress protein of the pathogen against which the enhanced response is desired.

### Claim 4 (depends on 3)

A vaccine of claim 3 in which the stress protein is selected from the group consisting of: mycobacterial stress proteins, bacterial stress proteins, fungal stress proteins, viral stress proteins and parasitic stress proteins.

### Claim 5

A composition comprising all or a portion of a selected stress protein, for use in producing or enhancing an immune response in an individual, wherein the stress protein is in sufficient quantity to elicit the desired immune response.

### Claim 6

A composition comprising a stress protein for use in immunizing an individual against a subsequent infection by a pathogen, wherein the stress protein is in sufficient quantity to produce an immune response to the stress protein.

### Claim 7 (depends on 6)

The composition of claim 6 wherein the stress protein is a stress protein of the pathogen.

### Claim 8

A composition comprising all or a portion of a stress protein or all or a portion of a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of the stress protein for use in inducing in an individual immune tolerance against a protein, under conditions appropriate for induction of the desired tolerance.

### Claim 9 (depends on 8)

A composition of claim 8, wherein the protein is a protein associated with rheumatoid arthritis.

### Claim 10

A vaccine for use in inducing an immune response in an individual comprising all or a portion of a stress protein or all or a portion of a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of the stress protein conjugated to a substance to which an immune response is desired or to a portion of the substance sufficient to induce an immune response in an individual.

### Claim 11 (depends on 10)

A vaccine of claim 10 in which the stress protein is a mycobacterial stress protein or a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of the mycobacterial stress protein to induce an immune response in an individual to whom it is administered.

### Claim 12 (depends on 10)

A vaccine of claim 10 in which the substance against which an immune response is desired is selected from the group consisting of: proteins, peptides, oligosaccharides, lipids, carbohydrates, organic molecules and a combination thereof.

### Claim 13

A vaccine for use in inducing an immune response in an individual comprising a recombinant fusion protein which includes all or a portion of a stress protein or all or a portion of a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of the stress protein fused to a substance against which an immune response is desired or to a portion of the substance sufficient to induce an immune response in an individual.

### Claim 14 (depends on 13)

A vaccine of claim 13 in which the stress protein is a mycobacterial stress protein or a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of the mycobacterial stress protein to induce an immune response in an individual to whom it is administered.

### Claim 15 (depends on 14)

A vaccine of claim 14 in which the protein is the HIV gag or pol protein.

### Claim 16

A composition for use as an agent to induce immune tolerance, comprising a stress protein conjugated to a substance to which an immune response is desired.

### Claim 17

A vaccine for use in enhancing in an individual an immune response, comprising all or a portion of a stress protein conjugated to a substance to which an immune response is desired or to a portion of the substance sufficient to enhance an immune response in the individual.

### Claim 18 (depends on 17)

A vaccine of claim 17 in which the stress protein is selected from the group consisting of: mycobacterial stress proteins, bacterial stress proteins, fungal stress proteins, viral stress proteins and parasitic stress proteins.

### Claim 19

A composition comprising a stress protein for use in producing or enhancing an immune response in an individual, wherein the stress protein is in sufficient quantity to elicit the desired immune response, and the stress protein is conjugated to a substance against which an immune response is desired or to a portion of the substance sufficient to produce or enhance an immune response in the individual.

### Claim 20

A composition comprising a stress protein for use in immunizing an individual against a subsequent infection by a pathogen, wherein the stress protein is in sufficient quantity to produce an immune response sufficient to protect the individual against subsequent infection by the pathogen, and the stress protein is conjugated to a substance against which an immune response is desired or to a portion of the substance sufficient to produce an immune response in the individual.

### Claim 21

A vaccine for use in inducing an immune response in an individual comprising all or a portion of a stress protein or all or a portion of a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of the stress protein and a substance against which an immune response is desired or to a portion of the substance sufficient to induce an immune response in an individual.

### Claim 22 (depends on 21)

A vaccine of claim 21 in which the stress protein is a mycobacterial stress protein or a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of the mycobacterial stress protein to induce an immune response in an individual to whom it is administered.

### Claim 23 (depends on 21)

A vaccine of claim 21 in which the substance against which an immune response is desired is selected from the group consisting of: proteins, peptides, oligosaccharides, lipids, carbohydrates, organic molecules and any combination thereof.

### Claim 24

A composition for use as an agent to induce immune tolerance, comprising a stress protein and a substance to which an immune response is desired.

### Claim 25

A vaccine for use in enhancing in an individual an immune response, comprising all or a portion of a stress protein and either a substance to which an immune response is desired or a portion of the substance sufficient to enhance an immune response in the individual.

### Claim 26 (depends on 25)

A vaccine of claim 25 in which the stress protein is selected from the group consisting of: mycobacterial stress proteins, bacterial stress proteins, fungal stress proteins, viral stress proteins and parasitic stress proteins.

### Claim 27

A composition comprising a stress protein and a substance against which an immune response is desired or a portion of the substance sufficient to produce or enhance an immune response in an individual for use in producing or enhancing an immune response in an individual, wherein the stress protein is in sufficient quantity to elicit the desired immune response .

### Claim 28

A composition comprising a stress protein and a substance against which an immune response is desired or to a portion of the substance sufficient to produce or enhance an immune response in the individual for use in immunizing an individual against a subsequent infection by a pathogen, wherein the stress protein is in sufficient quantity to produce an immune response sufficient to protect the individual against subsequent infection by the pathogen.

### Claim 29

A composition for use as an agent to induce an immune response in an individual to whom it is administered, comprising all or a portion of a stress protein or all or a portion of a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of the stress protein to be capable of inducing an immune response in an individual to whom it is administered.

### Claim 30

A composition for use as an agent to induce an immune response in an individual to whom it is administered, comprising all or a portion of a stress protein or all or a portion of a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of the stress protein conjugated to a substance against which an immune response is desired or to a portion of the substance sufficient to induce an immune response in the individual.

### Claim 31

A composition for use as an agent to induce an immune response in an individual to whom it is administered, comprising a recombinant fusion protein which includes a) all or a portion of a stress protein or all or a portion of a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of the stress protein and b) a substance against which an immune response is desired or a portion of the substance sufficient to induce an immune response in the individual.

### Claim 32

A composition for use as an agent to induce immune tolerance, comprising a stress protein.

### Claim 33

A composition for use in treating an autoimmune disease, comprising all or a portion of a stress protein or all or a portion of a protein having an amino acid sequence sufficiently homologous to the amino acid sequence of the stress protein to induce immune tolerance in an individual to whom it is administered.

### Claim 34 (depends on 36)

A composition of claim 36 for treating rheumatoid arthritis.

### Claim 35

A conjugate comprising a stress protein joined with a substance against which an immune response is desired.

### Claim 36 (depends on 35)

The conjugate of claim 35 wherein the stress protein is the hsp70 or the hsp60 protein.

### Claim 37 (depends on 35)

The conjugate of claim 35 wherein the substance is selected from the group consisting of: proteins, peptides, oligosaccharides, lipids, carbohydrates, organic molecules and combinations thereof.

### Claim 38 (depends on 37)

The conjugate of claim 37 wherein the protein is selected from the group consisting of: ovalbumin, influenza virus hemagglutinin protein, human immunodeficiency virus gag protein and human immunodeficiency virus pol protein.

### Claim 39

A fusion protein comprising a stress protein fused to a protein against which an immune response is desired.

### Claim 40 (depends on 39)

The fusion protein of claim 39 wherein the stress protein is a heat shock protein and the protein is a human immunodeficiency viral protein.

### Claim 41 (depends on 40)

The fusion protein of claim 40 wherein the heat shock protein is hsp70 and the human immunodeficiency viral protein is p24 protein.

### Claim 42

A method of generating antibodies to a substance comprising the steps of:
a) introducing an effective amount of a conjugate comprised of a stress protein joined to the substance into a mammalian host;
b) removing the antibodies produced by the host to the substance from the host; and
c) purifying the antibodies thereby generating antibodies to the substance.
